Grove AI, Inc.

Founded in 2024 and based in California, US, Grove AI, Inc. is focused on developing AI-driven solutions for clinical trial participant engagement. Sohit Gatiganti and Trân Lê are the co-founders of the company. In January 2026, Hippocratic AI, Inc.

, portfolio company of Kleiner Perkins, General Catalyst Partners, Greycroft, Andreessen Horowitz, SV Angel, CapitalG, Avenir Growth Capital, and NVentures acquired Grove AI, Inc. from Upfront, Pear VC, Afore Capital, LifeX Ventures, and A-Star Partners. Financial terms were not disclosed. Grove AI specializes in providing data-driven artificial intelligence solutions aimed at enhancing the recruitment and engagement of participants in clinical trials.

The company’s primary product, Grace, operates around the clock to facilitate participant interactions, streamline appointment scheduling, and improve operational efficiency within clinical research settings. The system qualifies candidates by analyzing a vast database of leads, ensuring that only the most suitable participants are connected to relevant trials. By focusing on optimizing participant relationships, Grove AI addresses challenges in clinical trial recruitment and retention, aiming to increase screening pass rates and improve participant engagement across diverse populations. The company’s revenue model is primarily based on subscription and partnership agreements with clinical research organizations and sites.

These partnerships entail the integration of their AI-driven services into existing trial frameworks, allowing for streamlined participant recruitment and engagement. The company generates revenue through transaction structures that may include tiered subscription plans based on the number of active trials and the services utilized, such as automated participant outreach and onboarding. The January 2026 acquisition will enable Hippocratic AI, Inc. to enhance its patient and clinical engagement abilities by bringing Grove AI’s technology and team into its life sciences division.